"DPP-4 Inhibitors Tied To Increased Risk Of IBD In Type 2 Diabetes" - Marilynn Larkin
In the first population-based study of its kind, researchers have found an association between use of dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly used to treat type 2 diabetes, and a significantly increased risk of inflammatory bowel disease (IBD). Ronald Tamler, MD, associate professor of medicine, endocrinology, diabetes and bone disease at the Icahn School of Medicine at Mount Sinai and director of Mount Sinai’s Clinical Diabetes Institute, called the findings “new and completely unexpected.” He added that “none of the larger trials and meta-analyses for this medication class over the last 12 years has surfaced this link.” He concluded that, “It is clear more studies are needed. In the meantime, patients whose diabetes is controlled with this generally well-tolerated class of medication should not discontinue their DPP-4 inhibitors and should discuss their treatments options with their doctor.”
- Ronald Tamler, MD, Associate Professor, Medicine, Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, Director, Mount Sinai Clinical Diabetes Institute